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Modification of proteins by ubiquitin or ubiquitin-like
proteins (UBLs) is a critical cellular process impli-
cated in a variety of cellular states and outcomes. A
prerequisite for target protein modification by a
UBL is the activation of the latter by activating en-
zymes (E1s). Here, we present the crystal structure
of the non-canonical homodimeric E1, UBA5, in com-
plex with its cognate UBL, UFM1, and supporting
biochemical experiments. We find that UBA5 binds
to UFM1 via a trans-binding mechanism in which
UFM1 interacts with distinct sites in both subunits
of the UBA5 dimer. This binding mechanism requires
a region C-terminal to the adenylation domain that
brings UFM1 to the active site of the adjacent UBA5
subunit. We also find that transfer of UFM1 from
UBA5 to the E2, UFC1, occurs via a transmechanism,
thereby requiring a homodimer of UBA5. These find-
ings explicitly elucidate the role of UBA5 dimerization
in UFM1 activation.INTRODUCTION
Post-translational modification of proteins by ubiquitin (Ub) or
Ub-like proteins (UBLs) is essential for cell survival. These mod-
ifications control nearly every cellular pathway by altering the
structure, localization, or enzymatic activity of proteins (Herr-
mann et al., 2007; Hochstrasser, 2009; Kerscher et al., 2006).
Three classes of enzymes function together to add Ub or UBLs
to target protein. The first enzyme, E1, activates the C terminus
of Ub or UBL through consecutive adenylation and thioesterifi-
cation reactions. E1 then transfers Ub or UBL to a cysteine
(Cys) side chain in the E2 enzyme via a transthioesterification re-
action. Then, the E2 and E3 enzymes together transfer the Ub or
UBL from the E2 enzyme to the substrate (Capili and Lima, 2007;
Pickart and Eddins, 2004).
To date, eight E1 enzymes, each with specificity toward Ub
or one UBL, are known as initiators of the modification process
and are divided into two groups: canonical and non-canonical
E1 enzymes (Schulman and Harper, 2009). While the canonicalCell Report
This is an open access article under the CC BY-NE1 enzymes, such as the cognate E1 enzymes for Ub, Nedd8
and SUMO, possess distinct adenylation and catalytic Cys do-
mains, the non-canonical E1 enzymes are missing the catalytic
Cys domain but contain a Cys embedded within the adenylation
domain that forms the thioester bond with the UBL (Schulman
andHarper, 2009).Moreover, while canonical E1s aremonomers
or heterodimers, the non-canonical E1s are all homodimers.
However, why non-canonical E1s exist as homodimers and
whether this is related to the lack of a Cys domain is yet not clear.
The non-canonical E1 group includes three members, ATG7,
UBA4, and UBA5, which are the cognate E1 enzymes of ATG8/
12, URM1, and UFM1, respectively (Furukawa et al., 2000; Ichi-
mura et al., 2000; Komatsu et al., 2004; Mizushima et al., 1998a,
1998b).
UFM1 (Ub-fold modifier 1) is one of the most recent UBLs
to be discovered; like other UBLs, it shows low sequence
identity to Ub but shares the Ub b-grasp fold (Komatsu et al.,
2004). In contrast to Ub that is present in all eukaryotic organ-
isms, UFM1 is absent in fungi but exists in plants and animals
(Grau-Bove´ et al., 2015). The biological roles of UFM1 are
largely unknown, and less than five substrates have been identi-
fied as of 2016. It has been suggested that UFM1 is involved in
ER stress and fatty acid metabolism (Azfer et al., 2006; Cai
et al., 2015; Hertel et al., 2013; Lemaire et al., 2011). Further-
more, the involvement of UFM1 in human diseases, including
cancer, schizophrenia, ischemic heart diseases, and diabetes,
has been reported over the last few years (Azfer et al., 2006;
Lemaire et al., 2011; Rubio et al., 2013; Yoo et al., 2014).
UBA5 is the smallest and structurally simplest E1. The UBA5
adenylation domain forms dimers, similar to ATG7, but whether
dimerization is required for UFM1 activation is not clear (Bacik
et al., 2010). The active site Cys of UBA5 (Cys 250) is located
within the adenylation domain, but this domain is not sufficient
for the formation of a thioester bond between the UFM1 C termi-
nus and the UBA5 catalytic Cys (Bacik et al., 2010). It has been
shown that a region outside this domain is required for UFM1
binding and activation (Habisov et al., 2016). This is similar to
the non-canonical E1, ATG7, in which a helical region C-terminal
to the adenylation domain is required for ATG8 binding and acti-
vation (Noda et al., 2011). In that case, ATG8 initially binds to the
helical domain in ATG7, located outside the adenylation domain,
and then binds to the adenylation domain while dissociating from
the helical domain. Therefore, it has been proposed that ATG8s 16, 3113–3120, September 20, 2016 ª 2016 The Author(s). 3113
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Data Collection and Refinement Statistics
Uba5-Ufm1 Uba5-Ufm1-AMP
Data Collection
Space group P3221 P3221
Cell dimensions
a, b, c (A˚) 138.08, 138.08,
99.17
139.87, 139.87,
99.74
a, b, g () 90, 90, 120 90, 90, 120
Resolution (A˚) 1.85 (1.95–1.85) 2.10 (2.21–2.10)
Rmerge 17.4 (177.9) 15.5 (62.4)
Mean I/sI 11.6 (1.9) 8.5 (3.5)
Completeness (%) 100.0 (100.0) 99.8 (99.5)
Redundancy 18.5 (18.3) 8.7 (8.9)
Rpim 4.2 (42.6) 5.5 (21.7)
CC1/2 99.9 (38.8) 99.6 (42.2)
Refinement
Resolution (A˚) 69.0–1.85 76.9–2.1
No. of reflections 88,360 65,664
Rwork/Rfree 18.7/20.6 19.8/22.1
No. of Atoms
Protein 5,080 5,040
Water 146 193
b factor (A˚2)
Protein 13.35 39.09
RMS deviations
Bond lengths (A˚) 0.015 0.006
Bond angles () 1.766 0.884
Ramachandran outliers (%) 0.78 0.47
Ramachandran favored (%) 97.19 97.63
MolProbity score 1.55 (93rd
percentile)
1.19 (100th
percentile)does not simultaneously bind both anchoring sites within ATG7.
Besides the role in UFM1 binding, the region located C-termi-
nally of the adenylation domain is involved in binding the E2,
UFC1 (Habisov et al., 2016; Xie, 2014). The canonical Ub-fold
domain (UFD) that is responsible for interaction between E1
and E2 is missing in UBA5, suggesting a different E2 binding
mechanism.
Although the steps required for UFM1 activation are likely
similar to those for Ub and other UBLs, the mechanism by which
UBA5 executes these steps is still not clear. Here we provide
structural and biochemical characterization of UFM1 activation
by UBA5. The crystal structure of the UBA5-UFM1 complex at
a 1.85 A˚ resolution shows that UBA5 undergoes conformational
changes upon UFM1 binding. These changes are concentrated
in the crossover loop (CL) comprising the active site Cys and
are critical for UFM1 adenylation and thioester bond formation.
Most importantly, we show that homodimerization of UBA5 is
required for UFM1 activation while UFM1 simultaneously binds
the UFM1-interacting sequence (UIS) of one UBA5 subunit and
the adenylation domain of the other subunit. We also show
that transfer of UFM1 from UBA5 to UFC1 is executed in a
trans-binding mechanism. In that case, UFC1 binds one UBA53114 Cell Reports 16, 3113–3120, September 20, 2016subunit and accepts the UFM1 that is bound to the other subunit.
Here, we provide the structural mechanism of UFM1 activation
and open new directions for specific intervention during UFM1
activation.
RESULTS AND DISCUSSION
Crystal Structure of the UBA5-UFM1 Complex
Habisov et al. (2016) showed that UFM1 non-covalently binds
UBA5 via a UIS located C-terminally of the adenylation domain.
This sequence, comprising nine amino acids (338–346), is critical
for UFM1 activation, and if removed, binding to UFM1 is negli-
gible (Habisov et al., 2016). Activation of a UBL requires interac-
tion with the adenylation domain of the E1, as observed in the
structures of Ub, SUMO, Nedd8, and ATG7, each with its
cognate E1 (Hong et al., 2011; Lee and Schindelin, 2008; Lois
and Lima, 2005; Noda et al., 2011; Olsen and Lima, 2013; Scha¨-
fer et al., 2014; Walden et al., 2003). To understand how UFM1
interacts with the UBA5 adenylation domain and the contribution
of the UIS to UFM1 activation, we determined the crystal struc-
ture of a UBA5-UFM1 complex at a 1.85 A˚ resolution (Table 1).
The crystallized UBA5 construct contained both the adenylation
domain and the UIS; thus, this complex provides significant
insight into UFM1 binding not observed in previous structures
of UBA5 (Bacik et al., 2010; Habisov et al., 2016). Crystals con-
tained twomolecules of UBA5 and twomolecules of UFM1 in the
P3221 asymmetric unit (Figure 1A). UBA5 retained the dimer or-
ganization as in the previous crystal structure of UBA5 alone,
suggesting that binding of UFM1 does not alter the UBA5 oligo-
meric state. In the structure, clear electron density was obtained
for the UIS but not for the residues that connect the UIS to the
adenylation domain, suggesting that these residues serve as a
flexible linker connecting the adenylation domain to the UIS (Fig-
ure S1). Because this linker was not apparent in the crystal struc-
ture, we modeled in the missing residues to confirm that the
sequence could span the distance. Unexpectedly, we found
that the linker is too short to connect the adenylation domain
and a UIS that bind the same UFM1 molecule. The distance be-
tween the terminal helix of the adenylation domain and the UIS is
51 A˚ for one monomer and 55 A˚ for the other monomer (Fig-
ure 1B). These distances cannot be spanned by the 10 and 13
amino acids that are not observed in the structure at 3.5 to
3.7 A˚ per amino acid. However, the linker is long enough to con-
nect the adenylation domain to a UIS that binds different UFM1
molecules. In that case, the distances are31 and40 A˚, which
can be spanned by 10 and 13 amino acids, respectively (Fig-
ure 1A). We further ruled out the possibility that the source of
the UIS is a symmetry-related UBA5 molecule (Figure S1). This
finding of a trans-binding mechanism for UFM1 is distinct from
that of other E1 enzymes. In our structure, each UFM1 binds to
both UBA5 molecules in the asymmetric unit through two inter-
action surfaces. One UFM1 binds to the UIS of UBA5 monomer
A and the adenylation domain of UBA5 monomer B, while the
other UFM1 binds to the UIS of monomer B and the adenylation
domain of monomer A. The UIS-UFM1 interaction resembles the
previously reported structure of UFM1 in complex with a UIS
peptide, thereby suggesting that the adenylation domain does
not alter the UIS-UFM1 interaction mode (Habisov et al., 2016).
Figure 1. Crystal Structure of the UBA5-
UFM1 Complex
(A) Complex of UBA5-UFM1 possessing two
molecules of UBA5 (blue) and two molecules of
UFM1 (orange) in the asymmetric unit. Dashed line
indicates disordered linker (not observed in the
structure) between the terminal helix of the UBA5
adenylation domain (helix 9) and the UIS. The
linkers connect an adenylation domain to a UIS
that bind different UFM1 molecules, thereby
implying a trans-bindingmechanism. a helices and
b strands are labeled a and b with numbers. The N
and C termini of UBA5 and UFM1 are labeled N
and C, respectively. UBA5 active site Cys 250
located at the CL adjacent to helix 8 is shown in the
stick representation.
(B) A model of a cis-binding mechanism of UFM1
to UBA5. In this model, dotted lines connect a UIS
and an adenylation domain that bind the same
UFM1 molecule, thereby suggesting a cismode of
binding. In that case, the distances between the
adenylation domain and the UIS are 55 and 51 A˚,
which are too long to be spanned by the 10 and 13
amino acids, respectively, that are missing in the
structure.In contrast to ATG8, which cannot simultaneously bind to both of
ATG7’s adenylation and C-terminal domains (Noda et al., 2011),
UFM1 binds both the adenylation and the UIS of UBA5 simulta-
neously. This structure thus suggests trans binding, in which the
UIS and the adenylation domain that bind one UFM1 derive from
different UBA5 molecules.
UFM1-UBA5 Adenylation Domain Interactions
The adenylation domain of UBA5 interacts with UFM1 opposite
to the UIS binding surface and buries 2,700 A˚2 of total surface
area (Figure 1). This is similar to the interaction surface between
ATG7 and ATG8 (2,930 A˚2) and slightly greater than that of the
E1 ancestor MoeB with MoaD (2,020 A˚2) (Lake et al., 2001;
Noda et al., 2011). It is also similar to the 2,530 A˚2 surface area
that is buried upon NEDD8 binding to the adenylation domain
of the canonical E1, UBA3. The adenylation domain of UBA5
binds to the b-grasp fold of UFM1 via the loop of UBA5 connect-
ing b strand 7 to helix 9 and the CL (Figures 2A and 2B). UFM1
Leu 16 and Pro 14, located at the loop connecting b strands
1–2, are in contact with UBA5 Phe 291, which is in the loop
connecting b strand 7 to the terminal helix. In addition, Met
295, Met 297, and Pro 301 in that loop interact with UFM1 Ile
50, Ile 55, and Ile 77 located in b strand 3 and its flanking loop
in b strand 4. This network of hydrophobic interactions resem-
bles the binding of proteins to Ub’s hydrophobic patch (Beal
et al., 1996).
The CL is a long loop region connecting b strand 6 and helix 8
of UBA5 and includes the active site Cys (Cys 250) (Figure 2B).
Upon UFM1 binding, the CL undergoes significant conforma-
tional changes compared to its structure in UBA5 alone (Baciket al., 2010). Specifically, in the UFM1-bound structure, residues
233–236 of UBA5 form a helical structure while the Ca of Leu 233
moves 10.8 A˚ relative to its position in the apo UBA5 structure
(Figure 2C). This movement is critical to prevent clashing with
UFM1 and to facilitate interactions between UBA5 and UFM1
(Figure 2B). Mutations that affect the interaction between
UFM1 and the CL (L233A and A230R/F within UBA5 or A48F/Q
within UFM1) abolish activation of UFM1 (Figure 2D) but, as ex-
pected, not the binding to UFM1, which is mediated via the UIS
(Figure S2). This is similar to ATG7, in which mutations in the
adenylation domain prevent activation of ATG8 but not binding
(Noda et al., 2011). Although the active site Cys in the UBA5
apo structure is located at the N terminus of helix H, this Cys is
no longer part of a helical structure in our complex with UFM1
(Figure 2C). Rather, Cys 250 resides in a loop structure in one
monomer within the asymmetric unit and is disordered in the
other monomer. This suggests that the position of the active
site Cys is changed upon binding to UFM1, and this involves
rearrangements of secondary structure elements. Conforma-
tional changes in the CL upon UBL binding are common to other
E1 enzymes, including the E1 enzymes for ATG8 and NEDD8
(Noda et al., 2011; Walden et al., 2003). However, in the UBA5
structure part of the CL is still missing, while in the structures
of the E1s for ATG8, Ub, NEDD8, and SUMO bound to their
respective UBL, this loop is preserved (PDB: 3VH3, 3CMM,
1R4N, and 1Y8R). Whether this indicates that UBA5 CL is
more flexible compared to other E1s and this required for
UFM1 activation is yet not clear.
UFM1 contains a C-terminal Val-Gly dipeptide instead of the
canonical Gly-Gly dipeptide present in Ub and other UBLs. InCell Reports 16, 3113–3120, September 20, 2016 3115
Figure 2. Structural Insight into UBA5 Adenylation Domain-UFM1 Interaction
(A) Interactions between the UBA5 loop connecting b strand 7 to helix 9 and the b-grasp fold of UFM1. UFM1 is shown in the surface representation, and UBA5 is
shown in the cartoon representation (blue). Residues involved in binding are shown in the stick representation.
(B) Interactions between the UBA5 CL and the b-grasp fold of UFM1. UFM1 is shown in the surface representation (light orange), and UBA5 is shown in the
cartoon representation (blue). Residues in the CL involved in binding are shown in the stick representation. Residues 244–249 are not observed in the structure, as
indicated by a dotted line.
(C) Conformational changes in the UBA5 CL upon UFM1 binding. Superposition of apo UBA5 (red) and UFM1-bound UBA5 (blue). The active sites Cys 250 and
Leu 233 are shown in the stick representation. Dotted lines in red and blue indicate themissing residues in the structure of UBA5 alone and in complex with UFM1,
respectively. In the zoomed view, the dotted yellow line indicates the movement of Leu 233 within the CL upon UFM1 binding. Red and black arrows indicate the
divergent point in the CL and the clashes the apo UBA5 CL forms with UFM1, respectively.
(D) Charging assay showing the effect of mutations in UBA5 CL or in UFM1 on activity.contrast to the E1 enzymes that activate Ub or SUMO, which
possess a small cavity that snugly fits the Di-Gly motif,
UBA5 has a larger space, enabling Val 82 of UFM1 to form
hydrophobic interactions with Val 207, Leu 254, and Met 258
of UBA5 (Figure 3A). The carbonyls of Val 82 and Arg 81 form
hydrogen bonds with the Arg 188 side chain, and mutating
this Arg to Ala prevents charging of UFM1 (Figures 3A and 3B).
Other residues in the UFM1 tail interact with UBA5 as well,
including Arg 79, Asp 80, and Arg 81, which form salt bridges
with UBA5 Glu 204, His 215, and Glu 209 (Figure 3A). In addition,
Arg 79 forms a hydrogen bond with UBA5 Gln 217. Mutating
these residues to Ala also precludes charging and slightly re-
duces binding to UFM1 (Figure 3B; Figure S2). This suggests
that the interaction of the adenylation domain with the tail of
UFM1 is critical for charging but not essential for UFM1 binding
to UBA5.3116 Cell Reports 16, 3113–3120, September 20, 2016Structural Insight into the Adenylation of UFM1 by UBA5
Superposition with the structure of ATP-bound UBA5 (PDB:
3H8V) indicates that the C-terminal Gly of UFM1 approaches
the ATP binding site of UBA5 (Figure 3C). The distance be-
tween the UFM1 C-terminal carbon and the a-phosphate is
3.2 A˚, which is similar to the distances observed in the E1s of
ATG7, SUMO, and NEDD8 (3.7, 4.2, and 4.1 A˚, respectively).
This suggests that the structure represents the Michaelis com-
plex before C-terminal adenylation and no further conforma-
tional changes are required for UFM1 adenylation. However,
the position of the UFM1 C-terminal carbon is 10.6 A˚ from
the active site Cys 250. This suggests, as proposed for other
E1 enzymes, that conformational changes in UBA5 are required
to bring the active site Cys into the vicinity of UFM1-AMP
mixed anhydride bond, leading to formation of the thioester
bond.
Figure 3. Structural Insight into UFM1 Adenylation by UBA5
(A) Contacts between the UFM1 C-terminal tail (orange) and the UBA5 adenylation domain (blue). Dotted lines indicate hydrogen bonds or salt bridges.
(B) Charging assay showing the effect of mutations in the UBA5 or UFM1 C-terminal tail on activation.
(C) UBA5 alignedwith the ATP-bound structure of UBA5 (PDB: 3H8V) tomodel the ATP to UFM1 distance. UBA5 is shown in the surface representation (blue), and
UFM1 is shown in the cartoon (orange) or stick representation. ATP and the UFM1 terminal Gly are shown in the stick representation. The dotted line indicates the
distance between the UFM1 C-terminal carbon and ATP a-phosphate.
(D) Structure of UBA5 (blue) in complex with UFM1 (pink) in the presence of AMP. AMP is shown in the stick representation, together with a simulated annealing
omit map contoured at 1.0s.
(E) Superposition of the UFM1C terminus in the absence of AMP (orange) and in the presence of AMP (pink). Only Gly 83 changes position in the presence of AMP.
The dotted line indicates the distance between the UFM1 C-terminal carbon and the ATP a-phosphate.To further understand the structural mechanism of UFM1 ad-
enylation, we attempted to crystallize adenylated UFM1 bound
to UBA5. We mutated the active Cys of UBA5 to Ala to prevent
the next step, i.e., thiol ester bond formation, and then we incu-
bated UBA5 with MgATP and UFM1 to form adenylated UFM1 in
complex with UBA5. The resulting crystals contained UBA5,
UFM1, and AMP, but surprisingly the AMP was not bonded to
the UFM1 C terminus (Figure 3D; Figure S3; Table 1). Because
no ATP was observed, this suggests that adenylation of UFM1
occurred but a water molecule hydrolyzed the linkage between
UFM1 and AMP. Given that the density for AMP was clear and
not a mixture of AMP and ADP, we believe the phosphoanhy-
dride bonds of ATP were not hydrolyzed and that ATP reacted
with UFM1. The half-times of amino acid-AMP linkages have
previously been found to be on the order 5 to 15 min at neutral
pH, and we crystallized UBA5-UFM1 at pH 7.5 (Demoss et al.,
1956). These data suggest that the relatively open active site of
UBA5 allowed entry of water, which hydrolyzed the mixed anhy-
dride bond before we were able to observe it in the crystal. This
finding differs from the crystal structures of the E1s of ATG8,
SUMO, and NEDD8 that were crystallized with their UBL andMgATP (Lois and Lima, 2005; Noda et al., 2011; Walden et al.,
2003). In those structures, the UBL C terminus was also free;
however, ATP, not AMP, was observed. This suggests that
adenylation did not occur. Our structure also differs from the
structures of Uba1 and MoeB in complex with adenylated Ub
and adenylated MoaD, respectively, in which the acyl-adenylate
is retained in the structures (Lake et al., 2001; Scha¨fer et al.,
2014). In our structure, the C-terminal Gly of UFM1 altered its
position compared to the structure of UBA5-UFM1 without
AMP (Figure 3E; Figure S3). This movement pushed the C-termi-
nal Gly of UFM1 away from the a-phosphate to a distance of 5 A˚.
Similar to the previously reported structure of ATP bound to
UBA5 (PDB: 3H8V), in which only one monomer binds ATP, our
structure possesses only one monomer with an AMP molecule
bound. Whether this indicates that UFM1 adenylation takes
place only on one UBA5 molecule within the homodimer is yet
not clear and calls for further research.
UBA5 Activates UFM1 in a Trans-Binding Mechanism
To test whether UBA5 activates UFM1 in a trans-binding
mechanism, as observed in our UFM1-UBA5 structure, weCell Reports 16, 3113–3120, September 20, 2016 3117
Figure 4. Trans-Binding Mechanism of UFM1 Activation by UBA5
(A) Charging assay testing the effect of UBA5 dimerization surface mutants. Each mutant D290K or K271D cannot activate UFM1 by itself. However, the mutants
together recover the ability to activate UFM1.
(B) UBA5 constructs of UBA5 used in this work. Each construct was subjected to active site C250A mutation or dimerization mutations as required.
(C) Charging assay showing that activation of UFM1 is executed in a transmechanism. UBA5 heterodimers enabling either cis or trans binding are tested for their
ability to activate UFM1.
(D) Charging of UFC1 with UFM1 by UBA5 is executed in a transmechanism. UBA5 heterodimers enabling either cis or trans binding of UFC1 are tested for their
ability to charge UFC1 with UFM1. In the absence of b-mercaptoethanol (BME), UFC1 possesses several bands that are not apparent in the presence of BME.engineered UBA5 constructs that were selective for trans or
cis binding. We identified two UBA5 mutants at the homodi-
merization interface (D290K or K271D) that would allow inter-
vention in only one subunit of the dimer. In the UBA5 dimer,
Asp 290 on one monomer forms a salt bridge with Lys 271
on the other monomer (Figure S4); therefore, in the mutant en-
zymes, this salt bridge is lacking and the individual mutants
cannot homodimerize. However, because these mutants
possess reciprocal mutations, we expected that incubating
these two mutants together would recover activity because
the salt bridge is present. As shown in Figure 4A, although
each mutant alone failed to activate UFM1, the mutant en-
zymes together successfully activated UFM1 to a level similar
to wild-type (WT) UBA5. The ability to recover activity with
these two mutants together but not alone suggests that these
are not structural mutations. In addition, although UBA5 has
been suggested to be a homodimeric protein based on its
crystal structure, here we demonstrate that homodimerization
of UBA5 is essential for activating UFM1.3118 Cell Reports 16, 3113–3120, September 20, 2016We next generated two UBA5 heterodimers: UBA5 (D290K,
C250A)-UBA5 (K271D DUIS) and UBA5 (D290K)-UBA5 (K271D
C250A DUIS). UBA5 bearing the active site Cys mutation
C250A cannot be charged with UFM1, while UBA5 missing the
UIS (ends at amino acid 329) cannot non-covalently bind
UFM1 (Figure 4B) (Habisov et al., 2016). This set of mutations en-
sures that in the UBA5 (D290K, C250A)-UBA5 (K271DDUIS) het-
erodimer binding to the UIS is mediated via one monomer and
charging, if it occurs, takes place on the other monomer, thereby
supporting a trans-binding mechanism. In the UBA5 (D290K)-
UBA5 (K271D C250A DUIS) heterodimer, binding to the UIS
and charging can only take place on the samemonomer, thereby
supporting a cis-binding mechanism. As shown in Figure 4C, we
detected charging of UFM1 only in the UBA5 heterodimer that
enables the trans-binding mechanism. We also mutated the sin-
gle Cys 250 in that heterodimer to Ala and showed that charging
activity is reduced to undetectable levels (Figure 4C). Altogether,
our results suggest that activation of UFM1 requires a UBA5
dimer, in which UFM1 binds the UIS of one monomer and the
adenylation domain of the other UBA5 monomer. This explicitly
explains the need for UBA5 dimerization in UFM1 activation.
UBA5 Charges UFC1 with UFM1 in a Trans-Binding
Mechanism
Although our structural and biochemical work strongly supports
a trans-bindingmechanism for UFM1, wewonderedwhether this
mechanism applied only to UFM1 or also applied to another sub-
strate of UBA5, the E2 enzyme UFC1. Therefore, to test how
UBA5 transfers UFM1 to UFC1, we made two UBA5 hetero-
dimers and tested their ability to transfer UFM1 to UFC1.
UBA5 binds UFC1 via a region located C-terminally of the UIS,
thereby UBA5 (D346), which ends after the UIS, does not bind
UFC1 (Figure 4B) (Xie, 2014). The first heterodimer we produced
was composed of UBA5 (K271DC250A)–UBA5 (D290KD346). In
this heterodimer, the UBA5 subunit that can form the thioester
bond with UFM1 is missing the UFC1 binding site. Therefore, if
charging of UFC1 occurs, then UFC1 accepts the UFM1 but
not from the UBA5 subunit that it binds (a trans-binding mecha-
nism). The other heterodimer UBA5 (K271D)–UBA5 (D290KD346
C250A) possessed the UFC1 binding site on the same UBA5
subunit that can form the thioester bond with UFM1. Therefore,
if charging of UFC1 occurs, then UFC1 accepts the UFM1 from
the UBA5 subunit that it binds (a cis-binding mechanism). As
shown in Figure 4D, we successfully obtained transfer of
UFM1 toUFC1 only in the UBA5 heterodimer that enabled a trans
mode of transfer. Moreover, to confirm that the UBA5 hetero-
dimer charges UFC1 on the active site Cys, C116, we mutated
this Cys to Ala and charging activity was abolished (Figure 4D).
This trans binding is similar to the mechanism by which ATG8
is transferred from ATG7 to the E2, ATG3. In that case, ATG3
binds one subunit of the homodimeric ATG7 and grabs the
ATG8 that is bound to the active site Cys of the other ATG7 sub-
unit (Noda et al., 2011). Overall, our results suggest that similar to
activation of UFM1, charging UFC1 with UFM1 requires a UBA5
dimer, in which UFC1 binds one UBA5 subunit and accepts the
UFM1 from the other subunit.
Conclusions
Here we present structural and biochemical insights into how
UBA5 binds UFM1 for activation and explain the need for
UBA5 dimerization in the mechanism of UFM1 activation. Bind-
ing of a UBL to the adenylation domain of its cognate E1 is
mandatory for activation. However, binding of a UBL to regions
outside the adenylation domain varies among the E1-activating
enzymes for different UBLs. Here we show that UFM1 binds to
the UIS of one UBA5 subunit, which facilitates interaction with
the adenylation domain of the other UBA5 subunit in the homo-
dimer. This demonstrates a UBL that simultaneously binds the
two subunits of its homodimeric E1 in a trans-binding mecha-
nism. We find that this trans-binding mechanism exists not
only for how UBA5 binds and activates UFM1 but also for the
transfer of UFM1 from UBA5 to the UFM1 E2 enzyme, UFC1.
In that case, UFC1 binds one UBA5 subunit and accepts the
UFM1 that is bound to the other UBA5 subunit. Thus, one subunit
of UBA5 holds the protein substrates, while the other subunit
catalyzes the activation of UFM1 and transfer to UFC1. Overall,
the trans-binding mechanism of UFM1 activation, which we pro-pose here, explicitly explains the role of UBA5 homodimerization
in UFM1 activation but at the same time calls for further investi-
gation as to why UBA5 functions via a trans mechanism as
opposed to a cis mechanism.EXPERIMENTAL PROCEDURES
Full details are provided in the Supplemental Experimental Procedures. The
human UBA5, UFC1, and UFM1, WT and mutants, were cloned into pET vec-
tors, expressed with N-terminal His tag in Escherichia coli, and purified using
metal affinity and size exclusion chromatography. Circular dichroism spectra
were measured to confirm that mutations did not affect protein structures.
Crystals of UBA5-UFM1 complexes with and without AMP were obtained us-
ing the hanging drop vapor diffusion method. Structures were determined by
molecular replacement using the crystal structure of UBA5 and the nuclear
magnetic resonance (NMR) structure of UFM1. Pull-down experiments were
performedwith Ni2+-nitrilotriacetic acid (NTA) beads, 63His-UFM1WTormu-
tants, and UBA5 WT or mutants. Pull-down results were analyzed by SDS-
PAGE and staining with Coomassie brilliant blue. Charging assays of UBA5
with UFM1 were performed by incubating UBA5 with UFM1 in the presence
of ATP and MgCl2. Charging was analyzed by non-reducing SDS-PAGE and
staining with Coomassie brilliant blue. For charging assays of UFC1 with
UFM1, we followed the UBA5 charging assay but with UFC1.ACCESSION NUMBERS
The accession numbers for the coordinates for the crystal structures of the
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